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Currently there is scientiﬁc and public con-
cern about whether exposure to ambient lev-
els of so-called endocrine disruptors, such as
p,p´-DDE [1,1-dichloro-2,2-bis(p-chloro-
phenyl)ethylene], a metabolite of DDT
[1,1,1-dichloro 2,2-bis(p-chlorophenyl)-
1,1,1-trichloroethane], and polychlorinated
biphenyls (PCBs), alter semen quality (1,2).
This concern stems from studies showing
that PCBs and p,p´-DDE are found in a large
proportion of the general population (3–5),
as well as animal and human studies suggest-
ing possible associations of exposure to PCBs
and p,p´-DDE with semen abnormalities and
altered testis function (6–8). The U.S.
Environmental Protection Agency (EPA)
National Human Adipose Tissue Survey esti-
mated that > 95% of the U.S. population
had detectable levels of PCBs (9). It is esti-
mated that > 99% of individuals have
detectable blood levels of p,p´-DDE (4).
PCBs and p,p´-DDE, the most stable
metabolite of DDT, are persistent, lipophilic
chemicals that are suspected endocrine
disruptors. DDT was widely used as an
insecticide, whereas PCBs were used in cut-
ting oils, lubricants, and as electrical insula-
tors. Although their use and manufacture
were banned nearly 30 years ago, they are
ubiquitous and persist in the environment;
PCBs are distributed worldwide as environ-
mental pollutants and have been measured
in air, water, aquatic, and marine sediments,
and in fish and wildlife (10). Furthermore,
they are biologically concentrated and stored
in human adipose tissue. The general popu-
lation continues to be exposed to PCBs and
p,p´-DDE through ingestion of contami-
nated food (fish, meat, milk, and their by-
products) and water, dermal contact (soil
and house dust), and inhalation (indoor air
in buildings that have various sources).
Many studies have suggested that sperm
concentrations (sperm counts) are declining
in men (2, 11–15). However, other studies
suggest that sperm counts are not declining
or may have increased marginally in some
areas (16–19). Although there is disagree-
ment on whether there is a downward tem-
poral trend in sperm counts, the studies
provide evidence that sperm counts vary by
geographic location (20). It has been hypoth-
esized that the geographic variation in sperm
concentrations may be due to environmental
exposures, lifestyle factors, or some unknown
causes (20). However, the population studies
published to date lack information at the
individual level on lifestyle factors, such as
cigarette smoking, which may adversely affect
semen quality, as well as information on
other potentially important environmental
exposures (21,22). Such studies were not
designed to investigate the relationship
between environmental exposures and sperm
concentration. Therefore, they are unable to
test the hypothesis that environmental agents
are associated with altered sperm counts.
To determine whether contemporary
ambient levels of PCBs and p,p´-DDE are
associated with altered semen quantity and
quality, we selected a study population
without specific exposure to PCBs or
p,p´-DDE. Detecting even an association of
small magnitude may have large population
effects because of the widespread distribu-
tion of PCBs and p,p´-DDE in the general
population.
Materials and Methods
The study was explained by the research
nurse to each potential subject, and any
questions they had were answered before
the subjects signed the consent form
approved by the Harvard School of Public
Health Institutional Review Board and the
Massachusetts General Hospital (MGH)
Human Subjects Committee.
Men presenting to the MGH Andrology
Laboratory for semen evaluation were asked
to participate. The number of men recruited
was limited because this study was funded as
a pilot study. Most of these men were part-
ners in couples undergoing medical evalua-
tion for an inability to conceive a pregnancy.
An individual man may or may not be infer-
tile/subfertile because the couple’s fertility
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This population was chosen for study for
three reasons. First, we wanted to study a
population without specific (i.e., occupa-
tional) exposure to PCBs or p,p´-DDE. The
exposure of these men therefore represents
contemporary ambient levels. Second, the
andrology laboratory population represents
men who are motivated to participate in the
study, making the study both feasible and
less subject to potential selection bias. Third,
the andrology laboratory population is
diverse, providing a population of men who
are representative of men in other clinics. 
Semen analysis. Semen collection and
analyses were performed at MGH in a clini-
cal setting and standardized manner. Because
the patient was already providing a semen
sample for clinical evaluation, we asked the
patient if the results of this sample could be
used for the research study. The andrologist
analyzed the semen sample without knowl-
edge of exposure; the serum samples were
analyzed for PCBs and p,p´-DDE several
months after the patient’s visit. All patients
are instructed by the clinic (routine previsit
instructions) to refrain from sexual activity
for at least 3 days before providing the semen
sample at the clinic, and information on the
period of abstinence (in days) was collected. 
Semen was collected in a sterile container
and allowed to liquefy for 20 min. The physi-
cal properties of the semen, including the
sample volume, pH, color, and viscosity were
recorded. We measured spermatozoa counts
and motility by computer-aided semen analy-
sis (CASA) using the Hamilton Thorne IVOS
10 Analyzer (Hamilton-Thorne Research,
Beverly, MA). To minimize variability (23),
we used a constant analysis setup and per-
formed additional quality control steps
including playback and viewing of quality
control plots in subjects with counts below 20
million/mL and above 50 million/mL. To
assess sperm morphology, a seminal smear
was made on a glass slide with < 5 µL of
semen, stained with Diff-Quik. We assessed
200 sperm using the Tygerberg Strict Criteria
(24). We used benzidine hydroxide staining
(25) to detect the presence of leukocytes in
the semen and distinguish them from other
round cells, including immature germ cells.
We used the World Health Organization
(WHO) reference values for evaluation of
infertility to deﬁne below normal values for
sperm concentration (< 20 million spermato-
zoa/mL) and sperm motility (< 50% motile
sperm or < 10 million total motile spermato-
zoa, accounting for individuals with low total
counts but high percent motility) (26). The
WHO reference values are based on manual
counting and manual assessment of motility.
The MGH study reference values for sperm
concentration and sperm motility are similar
to those recommended by the WHO (26).
The morphology criteria used to determine
below normal morphology was < 4% normal
morphology (Tygerberg Strict Criteria for
morphology) (24). Men that were above nor-
mal in all three semen parameters (sperm
count, motility, and morphology) were con-
sidered to have normal semen and were used
as a comparison population.
Questionnaire. All subjects were asked to
complete a self-administered detailed medical
history and lifestyle questionnaire. Each sub-
ject was given the questionnaire after he pro-
duced the semen sample and was asked to
complete the questionnaire at home and
return it by mail within 1 week. At the time
of the clinic visit for the semen analysis, the
subject was asked to report abstinence time
and medication use during the last 3 months.
Serum PCB, p,p´-DDE, HCB measure-
ments. Blood serum samples were analyzed
by the organic chemistry analytical labora-
tory at the Harvard School of Public Health.
Target analytes included 65 individual PCB
congeners, p,p´-DDE, and hexachloroben-
zene (HCB). Details of the sampling, analyt-
ical, and quality control procedures are
described elsewhere (27). Brieﬂy, the blood
samples were collected in red top vacutainer
tubes, and the serum fraction was separated
by centrifugation. Samples were stored in
solvent-rinsed glass vials with Teflon-lined
caps at –80oC until analysis.
For the extraction, we used procedures
developed by the Centers for Disease Control
(28) with modiﬁcations to conform to ultra-
trace–level analyses. These modifications
included additional cleaning of glassware and
dry reagents used in the column chromatog-
raphy cleanup and reducing the ﬁnal extract
volume to 100 µL. 
We measured percent lipid for each
serum sample gravimetrically by weighing an
aliquot of sample extract evaporated to dry-
ness. The mean ± SD percent lipid for the 29
samples were 0.75% ± 0.19. The serum
extracts were analyzed by gas chromatography
with electron capture detection (GC/ECD)
using a Hewlett-Packard 5890 Series II GC
with a fused silica capillary column (DB5, 30
m, 0.25 mm, 0.25 µm; J&W Scientific,
Folsom, CA). Quantitation was based on the
response factors of individual PCB congeners
and pesticides relative to the internal stan-
dard (PCB 166 by International Union of
Pure and Applied Chemistry nomenclature).
PCB concentrations were reported as indi-
vidual congeners and as the sum of all con-
geners assayed (ΣPCB). The amount of each
PCB congener in samples was corrected by
the amount of that analyte in the procedural
blank associated with the analytical batch.
We did not adjust results for surrogate
recoveries.
The PCB and p,p´-DDE concentrations
were adjusted for total serum lipids and are
expressed in units of nanograms per gram
total lipids. Consistent with ﬁndings in other
populations, the levels of total target PCB
congeners and p,p´-DDE in the serum sam-
ples were log normally distributed. PCB
congeners 118, 138, and 153 were especially
of interest because they are prevalent in
human serum, and the limited human data
suggest that they may be associated with
altered sperm motility (6). 
Quality assurance and quality control.
We validated the serum extraction procedure
before beginning sample analysis by analyz-
ing eight replicate samples of pooled serum
fortified with target analytes at 0.02 ng/g
serum. The mean ± SD percent recovery of
all PCB congeners added to the serum
matrix was 102 ± 13% and ranged from 73
to 125%. 
Method detection limits (MDLs) were
determined as three times the standard devia-
tion obtained from the analysis of the eight
serum samples fortiﬁed with target analytes,
as recommended in U.S EPA method (29).
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Table 1. Subject demographics (n = 29).
Number (%) Mean ± SD Minimum–maximum
Age (years) — 33 ± 4.6 25–45
Abstinence time (days) — 3.5 ± 2.2 0–10
Current smokers  3 (10) — —
Ex-smokers 3 (10) — —
Never smokers 23 (80) — —
Current drug (cocaine) use 0 (0) — —
Ex-drug (cocaine) use 9 (30) — —
Table 2. Distributions of p,p´-DDE, PCB 118, PCB 138, PCB 153, and ΣPCB among the 29 study participants.a
Mean ± SD Median Minimum Maximum
p,p´-DDE 255 ± 192 195 96.2 1,024
PCB 118 14.8 ± 8.9 12.5 4.8 42.3
PCB 138 28.6 ± 15.2 25.2 9.7 65.9
PCB 153 41.9 ± 18.8 39.3 12.5 81.8
Sum of PCB congeners 203 ± 78.1 201 67.7 358
aAdjusted for total serum lipids (nanogram per gram lipids).The MDL values for all PCB congeners and
HCB in serum were all < 0.05 ng/g, with
most of the congeners < 0.01 ng/g. The MDL
for p,p´-DDE was higher, but only because
unfortified serum had high p,p´-DDE con-
centrations at 6.3 ng/g.
Background contamination in both
batches was determined by procedural blanks.
The mean ± SD for the ΣPCB was 0.28 ±
0.14 ng/g. 
We evaluated analytical accuracy, preci-
sion, and extraction efficiency by analyzing
two pairs (one pair in each batch) of matrix
spike samples (aliquots of pooled serum
spiked with 0.15 ng/g of each target analyte
and two surrogate compounds, #11 and
#112, added to each sample at 0.4 ng/g).
The mean ± SD percent recovery for matrix
spike samples was 92 ± 3.6% for ΣPCB and
86 ± 7.4% for HCB. Matrix spike percent
recoveries for p,p´-DDE were inconsistent
because unfortified serum had high p,p´-
DDE concentrations (e.g., 6.3 ng/g) relative
to the amount of p,p´-DDE added (0.15
ng/g) from the spiking solution. The mean
± SD percent recovery for two surrogate
compounds, #11 and #112, were 99 ± 1.8
and 101 ± 4.2, respectively. Precision,
expressed as mean relative percent difference
(RPD) between matrix spike duplicates, was
4.3 ± 2.7.
In the blinded analysis of 10 split, unfor-
tified samples, the within-sample (within
run) coefﬁcient of variation (CV) for ΣPCB
was 7.5%; CVs for p,p´-DDE and HCB
were 4.7% and 6.2%, respectively.
Results
Of the 32 men asked to participate, 29
(90%) agreed to participate. The mean ± SD
age of the 29 participants was 33 ± 4.6 years
(range, 25–45 years). Three (10%) currently
smoked and 23 (80%) were never smokers
(Table 1). The mean ± SD abstinence time
was 3.5 ± 2.2 days (range, 0–10 days). 
Of the 29 subjects, 3 (10%) had sperm
concentrations < 20 million/mL, 7 (24%)
had < 50% motile sperm, 9 (31%) had < 4%
normal morphology, and 21 (72%) had
< 14% normal morphology. A subject may
be below normal in one or more semen para-
meters; this will not introduce bias or alter
the power of the study to detect an associa-
tion between exposure and outcome,
although care will be needed to account for
multiple comparisons. Six subjects (21%) in
the pilot study were below normal in more
than one semen parameter. Eighteen subjects
(62%) were normal for spermatozoa con-
centration, motility, and morphology.
These eighteen subjects were used as the
comparison subjects.
Distribution of PCBs and p,p´-DDE. It
is notable that the levels of p,p´-DDE in
serum were generally higher than the levels of
individual PCB congeners, which is also con-
sistent with other studies (6). In Table 2, the
distributions of p,p´-DDE, PCBs 118, 138,
153, and ΣPCB are described by their means
and standard deviations, medians, and mini-
mum and maximum values. 
The mean ± SD of the ΣPCB was 203 ±
78.1 ng/g lipids; the values ranged from 67.7
to 358 ng/g lipids, approximately a 5-fold
range. PCB congeners 118, 138, and 153
also showed about a 5- to 10-fold variation,
and their distributions were generally more
skewed than the distribution of the ΣPCB.
Associations described previously
between the sum of PCB concentrations and
specific PCB congeners (30,31) were con-
firmed in these analyses. The correlations
between individual congeners, ΣPCB, and
p,p´-DDE are shown in Table 3. Speciﬁcally,
a strong correlation was observed between
the sum of PCB concentrations and con-
gener 153 (r = 0.92, p < 0.05) and between
congeners 153 and 138 (r = 0.98, p < 0.05).
The strong correlations between specific
congeners and the sum of congeners (r >
0.7) make it difficult, though not impossi-
ble, to determine individual effects of a given
congener. 
In Table 4, the serum concentrations of
p,p´-DDE, PCBs 118, 138, 153, and ΣPCB
for subjects with below normal spermatozoa
concentration, motility, or morphology
(< 4%) are presented. Because below normal
values for semen parameters may be corre-
lated, we used subjects that were normal in
all three semen parameters (sperm concen-
tration, motility, and morphology) as the
comparison group. 
The data in Table 4 show that subjects
with below normal concentration, motility,
and morphology tend to have higher concen-
trations (both means and medians) of
p,p´-DDE, PCBs 118, 138, 153, and ΣPCB
than subjects normal in all three semen para-
meters. For instance, the mean ± SD values
for PCB 118 for subjects with below normal
sperm concentration, below normal motility,
or below normal morphology, as compared
to those subjects above normal in all three
parameters, was 20.9 ± 11.1, 20.6 ± 4.8, 19.6
± 4.2, and 12.8 ± 1.5 ng/g lipids, respec-
tively. Given the small sample size in the
study, we chose to present the data in tables
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Table 3. Spearman correlation coefﬁcients for p,p´-DDE, PCB 118, PCB 138, PCB 153, and ΣPCB 
p,p´-DDE PCB 118 PCB 138 PCB 153 ΣPCB
p,p´-DDE 1.0 0.34* 0.43** 0.37** 0.41**
PCB 118 1.0 0.76** 0.70** 0.69**
PCB 138 1.0 0.98** 0.91**
PCB 153 1.0 0.92**
Sum of PCBs 1.0
*Signiﬁcant at p < 0.10. **Signiﬁcant at p < 0.05.
Table 4. Serum concentration of p,p´-DDE, PCBs 118, 138, 153, and ΣPCB by below (↓) or above (↑) normal for spermatozoa concentration, motility, and morphology.
↓ Spermatozoa concentration ↓ Spermatozoa motility ↓ Spermatozoa morphology ↑ Concentration, motility,
Organochlorinea (< 20 million/mL) (n = 3) (< 50% motile) (n = 7) (< 4% normal) (n = 9) and morphology (n = 18)
p,p´-DDE
Median 222 240 180 189
Mean (SE) 448 (290) 354 (120) 278 (99.9) 240 (31.1)
PCB congener 118
Median 15.6 15.9 16.3 11.7
Mean (SE) 20.9 (11.1) 20.6 (4.8) 19.6 (4.2) 12.8 (1.5)
PCB congener 138
Median 25.5 37.9 25.5 21.4
Mean (SE) 30.8 (13.9) 37.4 (7.5) 32.8 (6.2) 26.6 (3.1)
PCB congener 153
Median 41.3 48.4 41.3 37.6
Mean (SE) 43.4 (18.5) 51.7 (8.3) 45.8 (7.3) 40.3 (4.1)
Sum of PCB congeners
Median 234 234 198 201
Mean (SE) 215 (80.4) 242 (34.0) 213 (32.0) 202 (16.6)
A subject may have contributed to more than one below-normal category.
aAdjusted for total serum lipids (nanogram per gram lipids).and figures, thereby allowing the reader to
view suggestive trends. We believe that the
number of subjects in the pilot study was too
small to warrant any formal statistical analysis
of the data set. For all three semen quality
outcomes (i.e., sperm concentration, motil-
ity, and morphology), the distribution of
potential confounders (i.e., subject age and
length of sexual abstinence before semen
sample collection) did not differ signiﬁcantly
between individuals with below and above
normal semen parameters. The abstinence
time for the below normal spermatozoa
group, below normal spermatozoa motility
group, below normal morphology group, and
the above normal group were 5.7 days
(range, 3–10), 4.8 days (3–10), 4.3 days
(2–10), and 3.2 days (0–7), respectively. The
above normal group had the shortest average
abstinence time, indicating that abstinence
time is not a likely explanation for the higher
semen parameters in this group. The age dis-
tribution for the below normal spermatozoa
group, below normal spermatozoa motility
group, below normal morphology group, and
the above normal group were remarkably
similar: 34.7 years (range, 25–45), 35.0 years
(29–45), 33.4 years (25–45), and 33.1 years
(27–43), respectively.
In Figures 1 and 2, individuals with
below normal motility (< 50% motile) are
compared to individuals that were above nor-
mal in all three semen parameters. The ﬁgures
show that a) there is a higher mean concen-
tration of PCB 118 and ΣPCB for individuals
with below normal motility as compared to
individuals with normal semen parameters,
and b) there is a wider distribution of expo-
sure concentrations among individuals with
below normal motility as compared to normal
individuals. For example, the mean serum
concentration of PCB 118 among the seven
men with abnormal motility was 20.6 ng/g
lipid as compared to 12.8 ng/g lipid for the
18 men with above normal motility, concen-
tration, and morphology. 
Discussion
This study presents the results from a pilot
study on the relationship between serum
PCBs and p,p´-DDE and semen quality in
29 subjects. Because the number of subjects
in this pilot study was too small to warrant
statistical analysis of the data set, the data
were presented as means and medians, com-
paring subjects with abnormal semen para-
meters to subjects with normal semen
parameters. The comparison subjects were
individuals with normal semen analysis
results for concentration, motility, and mor-
phology. The results show trends that are
suggestive of an association between PCBs
and p,p´-DDE and abnormal sperm count,
motility, and morphology. These trends 
justified further investigation in a full-scale
hypothesis-based study, currently in progress. 
The results of the pilot study show that
mean serum levels of PCBs were higher
among individuals with below normal motil-
ity as compared to comparison subjects with
normal sperm concentration, motility, and
morphology. Among individuals with below
normal motility, there was a wider distribu-
tion of exposure concentrations as compared
to the comparison subjects. The trends noted
for motility were also generally evident for
morphology; individuals with below normal
morphology (< 4%) had a wider distribution
of PCB concentrations and higher serum
PCB concentrations, on average, than com-
parison subjects. The data for sperm concen-
tration (i.e., sperm counts) also showed that
individuals with below normal sperm con-
centration had higher serum concentrations
of PCBs and p,p´-DDE than comparison
subjects. However, the standard errors were
large because the number of subjects was
small. For all three semen quality parameters,
the distribution of potential confounders
(i.e., subject age and length of sexual absti-
nence before semen sample collection) were
similar between individuals with below nor-
mal parameters and comparison subjects. 
We chose not to perform formal statisti-
cal analyses due to the small sample size in
the pilot study. However, we believe that
our data adequately summarize the results,
and we did not want to place undue empha-
sis on p-values or conﬁdence intervals gener-
ated in statistical tests. A full-scale study will
allow us to perform formal statistical analy-
ses and control for potential confounders.
The study subjects were recruited from
MGH, which is both a community hospital
and a tertiary health care facility. The com-
munity character of the hospital has further
developed as a result of the recent changes in
health care. The hospital owns three urban
health care centers and more than 100 pri-
mary care practices, making it the largest hos-
pital-affiliated primary care network in
eastern Massachusetts. These characteristics
ensure that the hospital serves a heteroge-
neous patient population that is representa-
tive of eastern Massachusetts. A review of the
MGH Andrology Laboratory patient visits
for the year before this study showed that the
patient population consisted of men from a
wide range of occupations (i.e., blue- and
white-collar jobs) and levels of socioeco-
nomic status. The patient area for the androl-
ogy laboratory includes neighborhoods in
and around Boston. The patient population
is also racially diverse. These characteristics
and attributes of the MGH Andrology
Laboratory population help ensure that the
study’s results are generalizable.
The recruitment of men from the MGH
Andrology Laboratory is unlikely to intro-
duce selection bias because it is unlikely that
participation in the study is dependent on
exposure; serum PCBs and p,p´-DDE were
determined only after entrance into study.
We also believe it is also unlikely that the
relationship between semen quality and
PCBs and p,p´-DDE in this clinic population
differs from the relationship in the general
population.
Several researchers have hypothesized
that chemicals with estrogen-like characteris-
tics, such as PCBs and DDT, are endocrine
disrupting and may adversely affect male
reproduction and lead to lower sperm counts
(1,2). Currently, the data in humans are lim-
ited, but several animal studies suggest that
these hypotheses are biologically plausible.
These chemicals, which readily penetrate
the blood–testis barrier, may directly affect 
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Figure 1. Serum concentrations of PCB congener
118 (adjusted for total serum lipids) plotted for sub-
jects with below normal motility (mean concentra-
tion 20.6 ng/g lipid) and for subjects with above
normal semen parameters (mean concentration
12.8 ng/g lipid). Bars indicate mean concentrations. 
Figure 2. Serum concentration of p,p´-DDE
(adjusted for total serum lipids) plotted for sub-
jects with below normal motility (mean concentra-
tion 353 ng/g lipid), and for subjects with above
normal semen parameters (mean concentration
240 ng/g lipid). Bars indicate mean concentrations.
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(n = 18)spermatogenesis (6,32). Effects at the mitotic
or meiotic level may lead to decreased sper-
matozoa production, and concentration of
the chemicals in male accessory glands and
seminal ﬂuid may lead to impaired spermato-
zoa motility (32). The estrogen-like charac-
teristics of PCBs are supported by evidence
showing that PCB metabolites bind to estro-
gen receptors (33). Jansen et al. (34) hypoth-
esized that the adverse reproductive affects of
PCBs may result from PCB congeners
increasing gonadotropin-releasing hormone
or affecting production and release of
luteinizing hormone from the pituitary.
Kelce et al. (7) showed that p,p´-DDE has
antiandrogenic and estrogenic properties and
may affect spermatogenesis through its
antiandrogenic activity. It is currently unclear
whether these mechanisms operate in
humans and whether general population
background levels of these compounds can
alter semen quality in men.
In one of the few published human stud-
ies, Bush et al. (6) analyzed 170 semen sam-
ples for PCBs and p,p´-DDE from fertile
men, men with idiopathic oligospermia, and
men after vasectomy. The mean of the total
PCBs (sum of all congeners) in the semen
samples was 5.8 ng/g (SEM 0.8). The
authors stated that these concentrations were
minimal and consistent with levels seen in
the general population; the semen sample
PCB concentrations were of comparable con-
centration to residues in human blood. Bush
et al. (6) found that in samples with a sperm
count < 20 million cells/mL, there was a sig-
nificant inverse relationship between sperm
motility and the concentration of PCB con-
geners 153, 138, and 118 (2,4,5,2´,4´,5´-
and 2,4,5,2´,3´,4´-hexachlorobiphenyl and
2,4,5,3´,4´-pentachlorobiphenyl, respec-
tively). These three congeners are major com-
ponents of Aroclor 1254 and 1260. The
magnitude of the effect on motility was large:
It ranged from 46% to 100%, and therefore
any of the maximum concentrations of the
three congeners would produce complete
lack of motility. Bush et al. (6) concluded
that the relationship between specific PCB
congeners and motility is both significant
and biologically important. The ﬁndings in
this study are both intriguing and disturbing
because the three congeners found to be
inversely predictive of sperm motility are
ubiquitous in the human population (35).
Further evidence of a possible relationship
between PCBs and semen quality is pre-
sented in a study in rats which suggests that
PCB exposure affects the ability of sperm to
fertilize eggs (36).
The current and ongoing research on
temporal trends in sperm concentration
emphasize the need for a better understand-
ing of the relationship between environmen-
tal exposures and semen quantity and
quality. Hypothesized environmental expo-
sures of interest include PCBs and pesticides.
Our full-scale study is currently in progress
and is designed to investigate the relation-
ship between environmental exposures and
testis function. The study includes assess-
ments of semen quantity and quality, as well
as measurements of reproductive hormones. 
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